Novo Nordisk (NVO)
(Delayed Data from NYSE)
$111.94 USD
-0.01 (-0.01%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $111.97 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.94 USD
-0.01 (-0.01%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $111.97 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Zacks News
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk (NVO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the most recent trading session, Novo Nordisk (NVO) closed at $140.99, indicating a +0.13% shift from the previous trading day.
Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now
by Kinjel Shah
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Novo Nordisk (NVO). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Take the Zacks Approach to Beat the Markets: Snap, Naspers, e.l.f. Beauty in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Novo Nordisk (NVO) closed the most recent trading day at $142.50, moving +0.01% from the previous trading session.
Earnings Growth & Price Strength Make Novo Nordisk (NVO) a Stock to Watch
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Best ETF Areas of Last Week
by Sanghamitra Saha
Wall Street was upbeat last week.
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
by Zacks Equity Research
Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Macy's and Five Below have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Macy's and Five Below have been highlighted as Zacks Bull and Bear of the Day
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, TotalEnergies, U.S. Bancorp and Flanigan's
by Zacks Equity Research
Novo Nordisk, TotalEnergies, U.S. Bancorp and Flanigan's are included in this Analyst Blog.
Top Analyst Reports for Novo Nordisk, TotalEnergies & U.S. Bancorp
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), TotalEnergies SE (TTE) and U.S. Bancorp (USB), as well as a micro-cap stock Flanigan's Enterprises, Inc. (BDL).
ECB Rate Cut Propels European Markets: 3 Must-Watch Stocks
by Tirthankar Chakraborty
Historic ECB rate cut bolstered European stocks, which calls for keeping a tab on Siemens (SIEGY), ASML Holding (ASML) and Novo Nordisk (NVO) for solid growth.
New to Investing? This 1 Medical Stock Could Be the Perfect Starting Point
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Beat the Market the Zacks Way: EverQuote, Micron, Amgen in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Eli Lilly (LLY) to Ramp Up Indiana Site for Mounjaro, Zepbound
by Zacks Equity Research
Since 2020, Eli Lilly (LLY) has committed more than $18 billion to building new manufacturing sites as well as updating existing manufacturing facilities.
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Qualcomm, Caterpillar, CSP and Epsilon Energy
by Zacks Equity Research
Novo Nordisk, Qualcomm, Caterpillar, CSP and Epsilon Energy are included in this Analyst Blog.
Why This 1 Medical Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Top Research Reports for Novo Nordisk, QUALCOMM & Caterpillar
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk (NVO), QUALCOMM (QCOM) and Caterpillar (CAT), as well as two micro-cap stocks CSP Inc. (CSPI) and Epsilon Energy Ltd. (EPSN).
Play These New ETFs to Tap Lucrative Weight Loss Drug Market
by Sanghamitra Saha
Global obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
by Zacks Equity Research
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.